Pacira BioSciences Inc. (82P)
XBER 
Summary
Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
Pacira BioSciences, Inc. ( PCRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Susan Mesco - Head of Investor Relations Frank Lee - CEO & Director Brendan Teehan - Chief Commercial Officer Shawn Cross - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Dennis Ding John Gionco - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Pacira BioSciences Third Quarter Earnings Conference Call.
Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Jonathan Slonin - Chief Medical Officer Shawn Cross - Chief Financial Officer Brendan Teehan - Chief Commercial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Gary Nachman - Raymond James Hardik Parikh - JPMorgan Serge Belanger - Needham Operator Good day, and thank you for standing by. Welcome to the First Quarter 2025 Pacira BioSciences Earnings Conference Call.
Pacira (PCRX) Q1 Earnings Surpass Estimates
Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago.
Pacira BioSciences Inc. (82P) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Pacira BioSciences Inc. ever had a stock split?
Pacira BioSciences Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Frank D. Lee CEO | XBER Exchange | US6951271005 ISIN |
| US Country | 788 Employees | - Last Dividend | - Last Split | 3 Feb 2011 IPO Date |
Overview
Pacira BioSciences, Inc. is a prominent company operating within the healthcare sector in the United States, focusing on creating innovative non-opioid pain management and regenerative health solutions. Established originally in 2006 and undergoing a name change from Pacira Pharmaceuticals, Inc. to Pacira BioSciences, Inc. in April 2019, the company has dedicated itself to addressing the urgent need for non-opioid therapeutic options. Based in Tampa, Florida, Pacira BioSciences stands at the forefront of developing, manufacturing, marketing, and distributing products designed to offer pain relief and support healing processes without the dependency risks associated with opioids. The company collaborates closely with healthcare practitioners to ensure the accessibility and effectiveness of its solutions, additionally forming strategic partnerships, such as with Aratana Therapeutics, Inc., to enhance its product offerings through development and commercialization agreements.
Products and Services
- EXPAREL
A cutting-edge bupivacaine liposome injectable suspension, EXPAREL is designed for postsurgical pain management. By utilizing a liposomal delivery system, it provides long-lasting pain relief without the need for opioids, offering a significant advantage in the postoperative care landscape.
- ZILRETTA
ZILRETTA is an extended-release injectable suspension formulated with triamcinolone acetonide. Engineered to manage osteoarthritis pain, it provides a sustained therapeutic effect, thereby enhancing patient comfort and mobility over an extended period.
- iovera° system
The iovera° system represents a groundbreaking approach to pain management through handheld cryoanalgesia technology. It works by applying controlled doses of cold to targeted nerves to temporarily reduce pain without drugs, making it an innovative non-opioid treatment option for various conditions.
- NOCITA
Developed through a strategic partnership with Aratana Therapeutics, Inc., NOCITA is another bupivacaine liposome injectable suspension offered by Pacira. It is specially designed for managing post-surgical pain in pets, extending the company’s non-opioid pain management solutions to the veterinary field.
Contact Information
